Get the latest news, insights, and market updates on BIO (Bio-Rad Laboratories, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […] Feb 19, 2026 - $BIO
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness
If you are wondering whether Bio-Rad Laboratories is starting to look attractively priced after a rough few years, this breakdown will help you put the current share price in context. The stock closed at US$256.56 most recently, with returns of a 14.9% decline over 7 days, 18.2% decline over 30 days, 16.0% decline year to date, 7.4% decline over 1 year, 46.9% decline over 3 years and 59.7% decline over 5 years. These moves have refocused attention on whether the market is being too cautious... Feb 15, 2026 - $BIO
Bio-Rad Laboratories (BIO) Returns To Profitability With Diagnostics Rebound – Is The Turnaround Durable?
In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside full-year 2025 sales of US$2.58 billion and net income of US$759.9 million. Beneath the mixed headline numbers, the Diagnostics segment returned to growth and the ddPCR portfolio gained traction, even as Bio-Rad absorbed a US$172.8 million impairment on purchased intangibles and continued to face... Feb 15, 2026 - $BIO
Assessing Bio-Rad Laboratories (BIO) Valuation After Prolonged Share Price Weakness
Bio-Rad Laboratories (BIO) has recently drawn investor attention after a period of weaker share performance, including a 12.3% decline over the past day and double digit negative returns over the past month and the past 3 months. See our latest analysis for Bio-Rad Laboratories. With the share price at US$256.56, Bio-Rad's recent 1 day and 7 day share price returns of 12.26% and 14.91% declines add to a weaker year to date share price return of 15.96%. The 1 year, 3 year and 5 year total... Feb 15, 2026 - $BIO
Bio-Rad Laboratories Q4 Earnings Call Highlights
Bio-Rad Laboratories (NYSE:BIO) executives said the company finished 2025 within revised guidance for revenue and operating margin, but acknowledged that gross margin performance fell short of internal expectations, particularly in the fourth quarter, as execution-related supply chain costs weighed Feb 13, 2026 - $BIO
Bio-Rad (BIO) Q4 2025 Earnings Call Transcript
Edward Chung: Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends for Bio-Rad Laboratories, Inc. With me on the call today are Norman D. Schwartz, our Chief Executive Officer; Jonathan P. DiVincenzo, President and Chief Operating Officer; and Roop K. Lakkaraju, Executive Vice President and Chief Financial Officer. Before we begin our review, I would like to remind everyone that we will be making forward-looking statements about management's goals, plans, expectations, our future financial performance, and other matters. Feb 12, 2026 - $BIO
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
HERCULES, Calif., February 12, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Feb 12, 2026 - $BIO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple